Review
Oncology
Raymond Uyiosa Osarogiagbon, Paul Van Schil, Dorothy J. Giroux, Eric Lim, Paul Martin Putora, Yolande Lievens, Giuseppe Cardillo, Hong Kwan Kim, Gaetano Rocco, Andrea Bille, Helmut Prosch, Francisco Suarez Vasquez, Katherine K. Nishimura, Frank Detterbeck, Ramon Rami-Porta, Valerie W. Rusch, Hisao Asamura, James Huang
Summary: The status of lymph node involvement is a crucial aspect of the TNM staging system for lung cancer. This study reviews the evidence for alternative approaches to classifying lymph node involvement and discusses the potential revisions for the next edition of the staging system. The findings contribute to the progress of lung cancer staging research.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Enrico Ruffini, Ramon Rami-Porta, James Huang, Usman Ahmad, Sarit Appel, Andrea Bille, Souheil Boubia, Cecilia Brambilla, Ayten Kayi Cangir, Vanessa Cilento, Frank Detterbeck, Conrad Falkson, Wentao Fang, Pier Luigi Filosso, Giuseppe Giaccone, Nicolas Girard, Francesco Guerrera, Maurizio Infante, Dong Kwan Kim, Marco Lucchi, Mirella Marino, Edith M. Marom, Andrew G. Nicholson, Meinoshin Okumura, Andreas Rimner, Charles B. Simone, Hisao Asamura
Summary: This article provides an update on the current staging of thymic epithelial tumors and highlights the unresolved issues for the upcoming ninth edition of the TNM classification. The study emphasizes the importance of the central thymic database for managing and analyzing data.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Frank C. Detterbeck, Katherine K. Nishimura, Vanessa J. Cilento, Meredith Giuliani, Mirella Marino, Raymond U. Osarogiagbon, Ramon Rami-Porta, Valerie W. Rusch, Hisao Asamura, Advisory Boards
Summary: Stage classification is fundamental in cancer management as it enables reporting results, comparing treatments, and assessing clinical relevance. The International Association for the Study of Lung Cancer (IASLC) is refining the stage classification for thoracic malignancies, using a sophisticated approach and a large international database for analysis. The goal is to ensure consistent discrimination and clinical applicability across different settings, treatments, and patients.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Hisao Asamura, Katherine K. Nishimura, Dorothy J. Giroux, Kari Chansky, Antje Hoering, Valerie Rusch, Ramon Rami-Porta
Summary: [
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Christine D. Berg, Joan H. Schiller, Paolo Boffetta, Jing Cai, Casey Connolly, Anna Kerpel-Fronius, Andrea Borondy Kitts, David C. L. Lam, Anant Mohan, Renelle Myers, Tejas Suri, Martin C. Tammemagi, Dawei Yang, Stephen Lam
Summary: Air pollution is the second leading cause of lung cancer and has a synergistic effect with smoking. This study summarizes the association between air pollution and lung cancer, as well as the identification and measurement methods of air pollutants. Assessing cumulative exposure to air pollution presents challenges in accurately collecting long-term data.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Meinoshin Okumura, Mirella Marino, Vanessa Cilento, Emily Goren, Enrico Ruffini, Daniel Dibaba, Usman Ahmad, Sarit Appel, Andrea Bille, Souheil Boubia, Cecilia Brambilla, Ayten Kayi Cangir, Frank Detterbeck, Conrad Falkson, Wentao Fang, Pier Luigi Filosso, Giuseppe Giaccone, Nicolas Girard, Francesco Guerrera, James Huang, Maurizio Infante, Dong Kwan Kim, Marco Lucchi, Edith M. Marom, Andrew G. Nicholson, Ramon Rami-Porta, Andreas Rimner, Charles B. Simone, Hisao Asamura
Summary: This article presents the proposed definitions for the T categories for the ninth edition TNM stage classification of thymic malignancies. The study analyzed data from a worldwide collective database of patients with thymic epithelial tumors and found that the proposed T categories provide good discrimination in outcome for the T component of the TNM-based stage system of thymic epithelial tumors.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ramon Rami-Porta
Summary: The classification of lung cancer based on tumor, lymph node, and metastases has undergone several revisions since its proposal in 1966. The upcoming 9th edition is expected to combine this classification with other prognostic factors to provide a more personalized prognosis for individual patients. International collaboration is crucial in building a comprehensive database to achieve this objective.
Article
Radiology, Nuclear Medicine & Medical Imaging
Hwayoung Song, Sung Hyun Yoon, Junghoon Kim, Jihang Kim, Kyoung Won Lee, Woojoo Lee, Seungjae Lee, Kwhanmien Kim, Choon-Taek Lee, Jin-Haeng Chung, Kyung Hee Lee
Summary: This study evaluated the prognostic performance of the proposed new N descriptors for clinical staging in nonsmall cell lung cancer patients without distant metastasis. The research revealed survival differences between different stages and some subgroups, providing insights into the impact on prognosis.
Review
Medicine, General & Internal
Lauren T. Erasmus, Taylor A. Strange, Rishi Agrawal, Chad D. Strange, Jitesh Ahuja, Girish S. Shroff, Mylene T. Truong
Summary: Lung cancer is the leading cause of cancer deaths in both men and women in the United States. Accurate staging is crucial for prognosis and treatment plans. The International Association for the Study of Lung Cancer (IASLC) has made revisions to the TNM staging system used for lung cancer, including modifications to T classification, description of regional lymph node spread in N classification, and classification of metastasis in M classification.
Article
Oncology
Steinar Solberg, Yngvar Nilssen, Odd Terje Brustugun, Per Magnus Haram, Aslaug Helland, Bjorn Moller, Trond-Eirik Strand, Sissel Gyrid Freim Wahl, Lars Fjellbirkeland
Summary: This study investigated the concordance between clinical and pathology staging of lung cancer patients and found a disappointingly low precision and concordance. There were significant differences in tumor diameter and staging categories reported, with some patients being upstaged or downstaged. These results highlight the need for improvement in lung cancer staging.
Article
Public, Environmental & Occupational Health
Xianghui Yang, Liyong Deng, Min Li, Yongjie Zhou, Guihua Wang
Summary: This study evaluated the association between socioeconomic status (SES) factors and cancer-specific survival (CSS) in patients with non-small cell lung cancer (NSCLC). A novel TNM-SES staging system was proposed, which showed superior predictive value compared to the traditional TNM stage.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Matthew P. Smeltzer, Giorgio Scagliotti, Heather A. Wakelee, Tetsuya Mitsudomi, Upal Basu Roy, Russell C. Clark, Renee Arndt, Clayton D. Pruett, Karen L. Kelly, Peter Ujhazy, Melissa L. Johnson, Yesim Eralp, Carlos H. Barrios, Fabrice Barlesi, Fred R. Hirsch, Paul A. Bunn
Summary: This study evaluated the impact of the COVID-19 pandemic on lung cancer clinical trials and the mitigation strategies implemented. The findings showed a decline in trial enrollment during the pandemic, but the use of mitigation strategies improved the situation.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Mehrdad Rakaee, Thomas K. Kilvaer, Simin Jamaly, Thomas Berg, Erna-Elise Paulsen, Marte Berglund, Elin Richardsen, Sigve Andersen, Samer Al-Saad, Mette Poehl, Francesco Pezzella, David J. Kwiatkowski, Roy M. Bremnes, Lill-Tove Rasmussen Busund, Tom Donnem
Summary: The study found that TLS score can be used to predict survival rates in NSCLC patients, with different scoring models and measurement methods having a significant impact on prognosis.
BRITISH JOURNAL OF CANCER
(2021)
Review
Critical Care Medicine
J. Matthew Archer, Mylene T. Truong, Girish S. Shroff, Myrna C. B. Godoy, Edith M. Marom
Summary: Lung cancer is a major cause of cancer-related mortality worldwide. Accurate clinical staging is crucial for predicting survival and determining treatment. The TNM-8 staging system proposed by the International Association for the Study of Lung Cancer in 2016 has become the standard method for lung cancer staging, applicable to all histologic subtypes of lung cancer. Understanding the strengths and limitations of imaging modalities and the details and potential issues with TNM-8 is important for optimizing patient care.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Review
Oncology
Mari Mino-Kenudson, Kurt Schalper, Wendy Cooper, Sanja Dacic, Fred R. Hirsch, Deepali Jain, Fernando Lopez-Rios, Ming Sound Tsao, Yasushi Yatabe, Mary Beth Beasley, Hui Yu, Lynette M. Sholl, Elizabeth Brambilla, Teh-Ying Chou, Casey Connolly, Ignacio Wistuba, Keith M. Kerr, Sylvie Lantuejoul
Summary: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has become the main treatment for advanced lung cancers. However, only a subset of patients respond to ICIs. The use of programmed death-ligand 1 (PD-L1) protein expression and tumor mutational burden (TMB) as predictive biomarkers has limitations. Ongoing research aims to find better immunotherapy biomarkers for treatment response and prognosis.
JOURNAL OF THORACIC ONCOLOGY
(2022)
